Key Stats for Telix Pharmaceuticals Stock
- Price change for Telix Pharmaceuticals stock: -9%
- $TLX Stock Price as of Aug. 21: $11
- 52-Week High: $13
- $TLX Stock Price Target: $21
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Telix Pharmaceuticals (TLX) stock climbed after the radiopharmaceutical company posted a strong first-half report.
- Revenue came in at AUD 477 million, up 22% from a year earlier,
- EBITDA jumped 146% to AUD 52 million.
- Net profit after tax reached AUD 38 million, a clear sign the company is turning sales growth into real earnings.
- The gains were driven largely by the company’s precision medicine business, which grew 27% to AUD 390 million.
- That’s mostly thanks to strong demand for its two imaging products, Illuccix and Gozellix.
- Gross margin in that segment also improved slightly to 65%.
- Telix said its PSMA imaging portfolio is now active in 24 countries and continues to pick up market share.
The company’s RLS distribution network, acquired last year, also helped. It brought in AUD 89 million in third-party revenue, up 10%, and AUD 57 million in internal revenue, up a sharp 70%.
Management pointed to a stronger manufacturing footprint across the U.S., Japan, Australia, and Belgium as a key reason the business can keep scaling.
Telix Pharmaceuticals stock closed the regular session at $11. That puts the stock just below its 52-week high of $12.60, and well above its 52-week low of $6.28.
Management left full-year 2026 revenue guidance unchanged at AUD 950 million to AUD 970 million, but said results should land near the top end of that range.
The company also raised its R&D spending outlook to AUD 230 million to AUD 270 million, roughly 24% to 28% of revenue, to support upcoming trials and regulatory work.
Several catalysts are on the calendar.
Pixclara has a U.S. decision date of September 11. Pixlumi is under review in Europe.
Zircaix is expected to be resubmitted to the FDA within one to two months.
ProstACT Global is moving toward a filing after another FDA meeting, and the BiPASS trial is close to finishing enrollment.
See analysts’ growth forecasts and price targets for Telix Pharmaceuticals stock (It’s free) >>>
What the Market Is Telling Us About Telix Pharmaceuticals Stock
The move higher in Telix Pharmaceuticals stock reflects a business that’s growing fast and getting more efficient at the same time.
EBITDA growing far faster than revenue is usually a good sign, since it means costs aren’t rising as quickly as sales.
That said, the stock’s reaction was solid but not explosive, which may reflect the fact that management kept guidance steady instead of raising it.
Investors seem to be treating this as confirmation of an existing growth story rather than a surprise.
With Telix Pharmaceuticals stock trading near its 52-week high and several regulatory decisions coming up in the next few months, the next moves may depend less on current sales and more on how those pipeline catalysts play out.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Telix Pharmaceuticals Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
